Precise Insertion of Large Genes, Human Stem Cell Therapy Innovation via a Dual-Virus Platform: High-Efficiency Knock-in of Large Gene Cassettes and Developmental Control Architecture Based on the TIVID Framework
-
Physical limits of site‑specific insertion of large genes and bottlenecks of conventional delivery platforms The ability to insert large gene cassettes site‑specifically into defined loci of human primary stem cells and induced pluripotent stem cells (iPSCs) is a core modality for treating heterogeneous refractory diseases. However, existing genome‑engineering guidelines suffer from a blind spot in which the physical size constraints of large DNA templates and cellular toxicity barriers cause a rapid collapse of delivery efficiency and target specificity. Conventional plasmid electroporation or single‑virus vector delivery systems fail to control false‑positive mutations and genotoxic noise arising from random genomic integration, creating a persistent technical bottleneck that stalls the development lead time of patient‑specific stem‑cell therapeutic pipelines.
-
TIVID hybrid architecture: Fusion of VLP‑driven RNP delivery and IDLV homology‑directed recombination To neutralize the entrenched delivery limitations and achieve programmable insertion of large genomic payloads, we fully deployed a dual‑viral delivery platform— the TIVID system— that physically couples virus‑like particles (VLPs) with integrase‑deficient lentiviral vectors (IDLVs). The team engineered virus‑like Cas9 edit particles with exceptional membrane‑penetration efficiency to pin‑point deliver Cas9 protein together with a single‑guide RNA (sgRNA) ribonucleoprotein (RNP) complex directly into the cytoplasm. Simultaneously, we co‑administered IDLVs, whose integration‑deficient design eliminates random genomic insertion risk, to safely supply large homology‑directed repair (HDR) donor templates, completing a dual‑gating molecular engineering strategy.
-
High‑efficiency genome knock‑in and precise editing of large cassettes in iPSC and HUDEP2 models When the established TIVID platform was applied to human iPSCs, it achieved a striking knock‑in efficiency of 65% ± 5%, far surpassing the limits of conventional platforms. Moreover, in the erythroid progenitor cell line HUDEP2, we demonstrated flawless insertion of a 7.1 kb HBB (β‑globin)‑GFP cassette precisely from cut site to cut site with zero base‑pair errors, thereby testing the payload capacity limit. This result isolates off‑target toxic noise below baseline levels that typically trigger cell death upon large‑gene delivery, preserving the intrinsic pluripotency of the cells and providing a robust preclinical screening asset.
-
Standardization of manufacturing specifications for programmable next‑generation cell and gene therapies (CGT) This dual‑viral, metabolism‑controlled matrix resets large‑gene correction guidelines from a simple exogenous delivery model to a fully integrated “RNP kinetics and non‑integrating viral template computationally synchronized genome‑engineering infrastructure.” We have built an engineering pipeline that simulates and optimizes the binding free energy between a single‑guide RNA sequence and a large donor cassette in silico in real time. The established TIVID docking matrix values will serve as a computational backbone for multinational pharmaceutical companies to prospectively calculate CMC (Chemistry, Manufacturing, and Controls) critical thresholds in IND filings for rare genetic blood‑disorder therapeutics, and will act as a master reference that can exponentially shorten global regulatory approval timelines for universal gene‑insertion platforms.
Nature Biomedical Engineering, Published May 2026. Summary: Overcoming the intrinsic cargo capacity thresholds and off-target genotoxicity bottlenecks that long limited the site-specific integration of large genes within human primary stem cells, this study details a programmable dual-viral delivery infrastructure termed TIVID. By pairing high-efficiency virus-like Cas9 edit particles for the transient intracellular delivery of Cas9/sgRNA ribonucleoprotein (RNP) complexes with non-integrating, integrase-deficient lentiviral vectors engineered to carry extended HDR donor templates, the framework optimizes homologous recombination kinetics. This unified biomimetic architecture achieved a robust knock-in efficiency of 65% ± 5% in human induced pluripotent stem cells (iPSCs) and demonstrated the flawless genomic integration of a 7.1 kb HBB-GFP cassette within primary erythroid progenitor HUDEP2 registries, establishing a scalable computational baseline for multiallelic human gene therapy.
The genomic‑engineering discoveries reported here extend beyond theoretical advances to directly empower the human stem‑cell therapeutic supply chain and the business pipeline for treating heterogeneous refractory diseases. First, applying the TIVID gene‑cassette to patient cohorts requiring large‑gene normalization—such as β‑thalassemia and sickle cell disease—eliminates the mutagenic noise generated by random genomic insertions, thereby preserving the in‑vivo safety profile of one‑shot cell therapies. Simultaneously, the high‑efficiency RNP carrier synthesis enabled by virus‑like particles allows virtual simulation of complex multiplexed gene‑editing scenarios and provides a platform interface to fine‑tune intracellular concentrations of the intended allelic insertions. Furthermore, during large‑scale, regulatory‑grade clinical development of stem‑cell‑derived therapies by multinational pharma, computational filtering of HLA‑type genetic background variability among subjects removes false‑positive batch errors in mass‑production specifications and functions as a backbone infrastructure that maximizes the probability of IND approval by global regulatory agencies.